Arcturus Therapeutics Holdings (ARCT) Cash from Operations (2018 - 2026)
Arcturus Therapeutics Holdings (ARCT) posted Cash from Operations of 19441000.0 for Q1 2026, down 19.81% on a QoQ basis from 16227000.0 in Q4 2025, and up 44.67% year-over-year from 13437943.5 in Q1 2025.
Arcturus Therapeutics Holdings (ARCT) Cash from Operations (2018 - 2026) Analysis & Trends
Arcturus Therapeutics Holdings' Cash from Operations history runs 9 years deep, the most recent figure standing at 19441000.0 for Q1 2026.
- Quarterly Cash from Operations rose 44.67% year-over-year to 19441000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 58574000.0 (up 34.43% YoY) and the FY2025 annual result came in at 74271000.0, down 24.31% from the prior year.
- Cash from Operations was 19441000.0 for Q1 2026 at Arcturus Therapeutics Holdings, down from 16227000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 160259000.0 in Q4 2022 and bottomed at 49039000.0 in Q1 2022.
- A 5-year average of 8209705.88 and a median of 19441000.0 in 2026 frame the typical range for Cash from Operations.
- Annual changes were most pronounced in 2022 — Cash from Operations soared 477.11% — and 2025, when it plunged 5613.73%.
- Arcturus Therapeutics Holdings' Cash from Operations stood at 160259000.0 in 2022, then tumbled by 100.39% to 629000.0 in 2023, then surged by 54.85% to 284000.0 in 2024, then plunged by 5613.73% to 16227000.0 in 2025, then declined by 19.81% to 19441000.0 in 2026.
- Business Quant data shows ARCT's Cash from Operations at 19441000.0 in Q1 2026, 16227000.0 in Q4 2025, and 17151000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -19.59 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 201.34 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.53 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.43 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.08 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -354.17 Mn |
| 10 | Arcturus Therapeutics Holdings | 164.57 Mn | -46.81 Mn | - | -19.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -19.44 Mn |
| Mar 31, 2026 | -19.44 Mn |
| Dec 31, 2025 | -16.23 Mn |
| Dec 31, 2025 | -16.23 Mn |
| Sep 30, 2025 | -17.15 Mn |
| Sep 30, 2025 | -17.15 Mn |
| Jun 30, 2025 | -5.76 Mn |
| Jun 30, 2025 | -5.76 Mn |
| Mar 31, 2025 | -35.14 Mn |
| Mar 31, 2025 | -35.14 Mn |
| Dec 31, 2024 | -284,000.00 |
| Dec 31, 2024 | -284,000.00 |
| Sep 30, 2024 | -23.76 Mn |
| Sep 30, 2024 | -23.76 Mn |
| Jun 30, 2024 | -30.14 Mn |
| Jun 30, 2024 | -30.14 Mn |
| Mar 31, 2024 | -5.56 Mn |
| Mar 31, 2024 | -5.56 Mn |
| Dec 31, 2023 | -629,000.00 |
| Dec 31, 2023 | -629,000.00 |